Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,252

Participants

Timeline

Start Date

October 15, 2007

Primary Completion Date

December 21, 2007

Study Completion Date

June 4, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

Fluarix

Single dose, Intramuscular injection

BIOLOGICAL

GSK Biologicals Influenza Vaccine GSK576389A

Single dose, Intramuscular injection

Trial Locations (29)

1319

GSK Investigational Site, Bekkestua

2317

GSK Investigational Site, Hamar

2408

GSK Investigational Site, Elverum

3717

GSK Investigational Site, Skien

5094

GSK Investigational Site, Bergen

5507

GSK Investigational Site, Haugesund

9000

GSK Investigational Site, Ghent

10365

GSK Investigational Site, Berlin

10367

GSK Investigational Site, Berlin

12601

GSK Investigational Site, Poughkeepsie

12687

GSK Investigational Site, Berlin

13086

GSK Investigational Site, Berlin

13507

GSK Investigational Site, Berlin

15106

GSK Investigational Site, Carnegie

15236

GSK Investigational Site, Pittsburgh

15562

GSK Investigational Site, Rüdersdorf

16506

GSK Investigational Site, Erie

33134

GSK Investigational Site, Coral Gables

33761

GSK Investigational Site, Clearwater

55318

GSK Investigational Site, Chaska

83527

GSK Investigational Site, Haag

84085

GSK Investigational Site, Langquaid

85635

GSK Investigational Site, Höhenkirchen-Siegertsbrunn

86150

GSK Investigational Site, Augsburg

88605

GSK Investigational Site, Messkirch

01757

GSK Investigational Site, Milford

08244

GSK Investigational Site, Somers Point

04129

GSK Investigational Site, Leipzig

N-1601

GSK Investigational Site, Fredrikstad

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00529516 - Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults | Biotech Hunter | Biotech Hunter